{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.3","upperLimit":"93.1","value":"86.6"},{"groupId":"OG001","lowerLimit":"70.2","upperLimit":"94.3","value":"85.0"}]}],"title":"BICR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.2","upperLimit":"94.9","value":"89.0"},{"groupId":"OG001","lowerLimit":"70.2","upperLimit":"94.3","value":"85.0"}]}],"title":"Investigator"}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Disease Control Rate (DCR), defined as the proportion of subjects who achieved CR, PR, or SD for a minimum of 6 weeks during study treatment; DCR based on BICR and DCR based on Investigator assessments assessed according to RECIST version 1.1. DCR was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"T-DXd 5.4 mg/kg Q3W"},{"description":"Participants were randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).","id":"OG001","title":"T-DXd 6.4 mg/kg Q3W"}],"paramType":"NUMBER","populationDescription":"DCR was assessed in the Full Analysis Set, which included 1 participant who was randomized/registered to T-DXd 6.4 mg/kg Q3W but actually received T-DXd 5.4 mg/kg Q3W.","reportingStatus":"POSTED","timeFrame":"From first dose administration to data cut off, up to approximately 19 months.","title":"Disease Control Rate Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) -Overexpressing Metastatic Colorectal Cancer","type":"SECONDARY","unitOfMeasure":"percentage of participants"}